e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adaptimmune Therapeutics plc - American Depositary Shares
(NQ:
ADAP
)
0.1401
-0.0134 (-8.73%)
Streaming Delayed Price
Updated: 11:11 AM EDT, Oct 6, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adaptimmune Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
April 28, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell...
Via
Newsfile
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
April 11, 2023
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
Via
The Motley Fool
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
April 11, 2023
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...
Via
Newsfile
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
March 30, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
March 06, 2023
Via
Benzinga
Adaptimmune Therapeutics's Earnings Outlook
March 03, 2023
Via
Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
March 07, 2023
Via
Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
March 06, 2023
TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to...
Via
Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 06, 2023
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
Expert Ratings for Adaptimmune Therapeutics
January 05, 2023
Via
Benzinga
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
November 08, 2022
Positive trial data is powering the biotech's stock higher today.
Via
The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
March 06, 2023
Via
Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
March 06, 2023
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of
Via
Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
March 06, 2023
A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors.
Via
InvestorPlace
ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
March 06, 2023
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 06, 2023
Via
Benzinga
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
March 06, 2023
BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed...
Via
Newsfile
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors...
Via
Newsfile
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
February 22, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...
Via
Newsfile
Adaptimmune Announces Changes to Board of Directors
February 16, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...
Via
Newsfile
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
January 31, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
January 09, 2023
-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel --...
Via
Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
December 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
December 23, 2022
- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial...
Via
Newsfile
Credit Suisse, Autodesk And Other Big Losers From Wednesday
November 25, 2022
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
November 18, 2022
- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after...
Via
Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
November 09, 2022
Upgrades
Via
Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
November 09, 2022
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 08, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Facebook
Twitter
YouTube